6 results about "Filamin" patented technology

To identify a causative gene for progressive supranuclear palsy to create effective therapeutic methods and therapeutic agents, and to provide useful means for developing the therapeutic methods and therapeutic agents.SOLUTION: In order to solve this problem, a therapeutic agent for progressive supranuclear palsy is provided, which contains a compound that inhibits expression of a filamin A gene. In addition, an evaluation system or the like using cells expressing filamin A is provided, which can be used to search and the like for the therapeutic agents or candidate agents for progressive supranuclear palsy.SELECTED DRAWING: None

A method of inhibiting phosphorylation of the tau protein and / or a TLR4-mediated immune response is disclosed. The method contemplates administering to cells in recognized need thereof such as cells of the central nervous system an effective amount of a of a compound or a pharmaceutically acceptable salt thereof that binds to a pentapeptide of filamin A (FLNA) of SEQ ID NO: 1, and contains at least four of the six pharmacophores of FIGS. 35-40.

Compounds represented by formula (I) belowand pharmacologically acceptable salts thereof and solvates of them; pharmaceutical compositions and dynamin-related protein 1 (Drp1)-filamin complex formation inhibitors containing them; and uses of the compounds, salts, solvates, pharmaceutical compositions, and (Drp1)-filamin complex formation inhibitors for use as a prophylactic or therapeutic agent.

A method of inhibiting phosphorylation of the tau protein and / or a TLR4-mediated immune response is disclosed. The method contemplates administering to cells in recognized need thereof such as cells of the central nervous system an effective amount of a of a compound or a pharmaceutically acceptable salt thereof that binds to a pentapeptide of filamin A (FLNA) of SEQ ID NO: 1, and contains at least four of the six pharmacophores of FIGS. 35-40.

The present application relates to the use of a polypeptide or antibody binding fragment thereof capable of forming an antigen-antibody complex with a biological sample obtained from the patient in the preparation of a reagent or kit for detecting vascular endothelial cell damage; wherein the polypeptide or antibody binding fragment thereof comprises at least two selected from the following group: alpha enolase protein (ENO1), ankle protein 1 (TLN1), filamin-A (FLNA), desmosomal linker protein (AHNAK), desmosomal core glycoprotein-1 (DSG1), myosin light chain 1 (MYL1), heat shock protein 90 beta (HSP90AB1), cytoskeleton-associated protein 4 (CKAP4), membrane spike protein (MSN). The vascular endothelial cell autoantibody of the present application can be used to diagnose vascular endothelial cell damage by simply detecting the titer in serum, which has very great clinical application value.

The invention discloses an application of a tear biomarker combination in preparation of a reagent or a kit for screening or auxiliary diagnosis of retinopathy (ROP) of a premature infant, and a corresponding kit. The biomarker combination comprises four proteins such as Src family kinase Lyn, filamin A (FLNA) and the like, and metabolites such as 3, 5-di-tert-butyl-4-hydroxybenzaldehyde (BHT-CHO), caffeine and the like. The detection sample is tears of a subject, and the reagent or the kit can be used for dividing the risk of the ROP into high risk, medium risk or low risk, and / or dividing the ROP diagnosis result into treatment, no treatment or no ROP. The biomarker is identified based on the leading-edge mass spectrometry technology, the limitation of traditional dependence on professional physicians and invasive detection is broken through, the method has the advantages of being non-invasive, easy and convenient to operate, objective, economical and the like, an existing screening diagnosis method can be effectively supplemented, ROP early-stage precise prevention and control can be promoted, and the method is especially suitable for areas lack of medical resources.